Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Dimitrios Stefanoudakis; Maximos Frountzas; Dimitrios Schizas; Nikolaos V. Michalopoulos; Alexandra Drakaki; Konstantinos G. Toutouzas

doi:10.3390/cimb46040177

Current Issues in Molecular Biology (Mar 2024)

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Dimitrios Stefanoudakis,
Maximos Frountzas,
Dimitrios Schizas,
Nikolaos V. Michalopoulos,
Alexandra Drakaki,
Konstantinos G. Toutouzas

Affiliations

Dimitrios Stefanoudakis: First Propaedeutic Department of Surgery, Hippocration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Maximos Frountzas: First Propaedeutic Department of Surgery, Hippocration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Dimitrios Schizas: First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Nikolaos V. Michalopoulos: First Propaedeutic Department of Surgery, Hippocration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Alexandra Drakaki: Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Konstantinos G. Toutouzas: First Propaedeutic Department of Surgery, Hippocration General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece

DOI: https://doi.org/10.3390/cimb46040177
Journal volume & issue: Vol. 46, no. 4
pp. 2827 – 2844

Abstract

Read online

The present review demonstrates the major tumor suppressor genes, including TP53, CDKN2A and SMAD4, associated with pancreatic cancer. Each gene’s role, prevalence and impact on tumor development and progression are analyzed, focusing on the intricate molecular landscape of pancreatic cancer. In addition, this review underscores the prognostic significance of specific mutations, such as loss of TP53, and explores some potential targeted therapies tailored to these molecular signatures. The findings highlight the importance of genomic analyses for risk assessment, early detection and the design of personalized treatment approaches in pancreatic cancer. Overall, this review provides a comprehensive analysis of the molecular intricacies of pancreatic tumors, paving the way for more effective and tailored therapeutic interventions.

Published in Current Issues in Molecular Biology

ISSN: 1467-3037 (Print); 1467-3045 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: https://www.mdpi.com/journal/cimb

About the journal

Abstract

Keywords